[go: up one dir, main page]

PE20160045A1 - Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados - Google Patents

Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados

Info

Publication number
PE20160045A1
PE20160045A1 PE2015002617A PE2015002617A PE20160045A1 PE 20160045 A1 PE20160045 A1 PE 20160045A1 PE 2015002617 A PE2015002617 A PE 2015002617A PE 2015002617 A PE2015002617 A PE 2015002617A PE 20160045 A1 PE20160045 A1 PE 20160045A1
Authority
PE
Peru
Prior art keywords
prefusion
rsv
polypeptides
soluble
respiratory syncitial
Prior art date
Application number
PE2015002617A
Other languages
English (en)
Inventor
Anders Krarup
Johannes Petrus Maria Langedijk
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of PE20160045A1 publication Critical patent/PE20160045A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2999/00—Further aspects of viruses or vectors not covered by groups C12N2710/00 - C12N2796/00 or C12N2800/00
    • C12N2999/002—Adverse teaching

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Polipetidos F de prefusion del virus sincicial respiratorio (RSV) estables, composiciones inmunogenicas que comprenden dichos polipeptidos y sus uso en la prevencion y/o el tratamiento de una infeccion por RSV. Estos polipeptidos comprenden al menos un epitope que presenta especificidad por la proteina de la conformacion de prefusion F. En ciertas formas de realizacion, los polipeptidos F de prefusion del RSV son solubles. La invencion tambien provee moleculas de acido nucleico que codifican los polipeptidos F de prefusion del RSV de acuerdo con la invencion y vectores que comprenden a dichas moleculas de acido nucleico
PE2015002617A 2013-06-17 2014-06-17 Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados PE20160045A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13172256 2013-06-17

Publications (1)

Publication Number Publication Date
PE20160045A1 true PE20160045A1 (es) 2016-02-18

Family

ID=48625910

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015002617A PE20160045A1 (es) 2013-06-17 2014-06-17 Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados

Country Status (20)

Country Link
US (1) US10294279B2 (es)
EP (1) EP3010931B1 (es)
JP (1) JP6679475B2 (es)
KR (1) KR102313153B1 (es)
CN (1) CN105408348B (es)
AP (1) AP2015008893A0 (es)
AU (1) AU2014283334B2 (es)
BR (1) BR112015031509B1 (es)
CA (1) CA2914792C (es)
CL (1) CL2015003655A1 (es)
EA (1) EA034653B1 (es)
HK (1) HK1223949A1 (es)
IL (1) IL243053B (es)
MX (1) MX362792B (es)
MY (1) MY171210A (es)
PE (1) PE20160045A1 (es)
PH (1) PH12015502735B1 (es)
SG (1) SG11201510216RA (es)
WO (1) WO2014202570A1 (es)
ZA (1) ZA201509140B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10899800B2 (en) 2013-04-25 2021-01-26 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
MX362792B (es) 2013-06-17 2019-02-13 Janssen Vaccines & Prevention Bv Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados.
KR20180026734A (ko) 2015-07-07 2018-03-13 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 융합-전 rsv f 폴리펩티드
EP3821906A1 (en) 2015-07-07 2021-05-19 Janssen Vaccines & Prevention B.V. Vaccine against rsv comprising modified f polypeptide
KR102136678B1 (ko) 2015-12-23 2020-07-22 화이자 인코포레이티드 Rsv f 단백질 돌연변이체
EP3439672B1 (en) * 2016-04-05 2020-11-25 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f protein for use in the prophylaxis of rsv infection
CA3018139A1 (en) 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
AU2017272504A1 (en) * 2016-05-30 2018-11-29 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion RSV F proteins
US11464848B2 (en) 2017-03-15 2022-10-11 Modernatx, Inc. Respiratory syncytial virus vaccine
MA47790A (fr) 2017-03-17 2021-05-05 Modernatx Inc Vaccins à base d'arn contre des maladies zoonotiques
KR102774312B1 (ko) 2017-04-04 2025-03-05 유니버시티 오브 워싱톤 파라믹소바이러스 및/또는 뉴모바이러스 f 단백질을 표시하는 자가-조립 단백질 나노구조체 및 이의 용도
AU2018269319A1 (en) 2017-05-15 2019-11-07 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
CN110769850A (zh) 2017-05-15 2020-02-07 扬森疫苗与预防公司 稳定的含病毒组合物
WO2018210871A1 (en) * 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
CA3061278A1 (en) * 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
EA202090738A1 (ru) 2017-09-15 2020-06-10 Янссен Вэксинс Энд Превеншн Б.В. Способ безопасного индуцирования иммунитета против rsv
EP3746090A4 (en) 2018-01-29 2021-11-17 ModernaTX, Inc. RSV RNA Vaccines
KR102725189B1 (ko) * 2018-11-01 2024-10-31 에스케이바이오사이언스(주) 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물
WO2020099383A1 (en) * 2018-11-13 2020-05-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
US20220273787A1 (en) 2019-05-15 2022-09-01 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
CA3140234A1 (en) 2019-05-15 2020-11-19 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
BR112021021637A2 (pt) * 2019-05-20 2021-12-21 Valneva Se Vacina de subunidade para tratamento ou prevenção de uma infecção do trato respiratório
WO2021046207A1 (en) 2019-09-04 2021-03-11 University Of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
CN115461076A (zh) 2020-04-02 2022-12-09 扬森疫苗与预防公司 稳定化的疫苗组合物
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
CN115161344A (zh) * 2022-04-26 2022-10-11 北京智飞绿竹生物制药有限公司 一种针对呼吸道合胞病毒感染的疫苗的制备方法
CN120076825A (zh) 2022-09-29 2025-05-30 辉瑞公司 包含rsv f蛋白三聚体的免疫原组合物
EP4578870A1 (en) * 2022-09-29 2025-07-02 Beijing Benewill Technology Development Co., Ltd. Respiratory syncytial virus recombinant fusion protein with prefusion conformation, and preparation method therefor and use thereof
AU2023349011A1 (en) * 2022-09-29 2025-04-17 Beijing Benewill Technology Development Co., Ltd. Respiratory syncytial virus recombinant fusion protein having pre-fusion conformation, and preparation method therefor and use thereof
CN120153078A (zh) 2022-10-27 2025-06-13 辉瑞大药厂 编码rsv-f的rna分子及含所述rna分子的疫苗
EP4608441A1 (en) 2022-10-27 2025-09-03 Pfizer Inc. Immunogenic compositions against influenza and rsv
US20240252612A1 (en) 2022-12-11 2024-08-01 Pfizer Inc. Immunogenic compositions and uses thereof
WO2024154048A1 (en) 2023-01-18 2024-07-25 Pfizer Inc. Vaccines against respiratory diseases
CN118108812B (zh) * 2023-05-04 2025-04-15 国药中生生物技术研究院有限公司 Rsv f蛋白的突变体
WO2025012756A1 (en) 2023-07-07 2025-01-16 Pfizer Inc. Amphiphilic tlr7/8 adjuvants and uses thereof
CN119462859A (zh) * 2023-08-09 2025-02-18 深圳瑞吉生物科技有限公司 呼吸道合胞病毒抗原性多肽、疫苗及其应用
WO2025059498A2 (en) * 2023-09-15 2025-03-20 Icosavax, Inc. Viral proteins and nanostructures and uses thereof
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
CN117736278B (zh) * 2023-12-25 2025-02-07 英诺特（唐山）生物技术有限公司 一种用于检测呼吸道合胞病毒感染的试剂盒及检测方法
CN117586358B (zh) * 2024-01-19 2024-08-13 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽
WO2025163460A2 (en) 2024-01-30 2025-08-07 Pfizer Inc. Vaccines against respiratory diseases
WO2025171026A1 (en) * 2024-02-07 2025-08-14 Pioneer Hi-Bred International, Inc. Methods and compositions to reduce undesirable phenotypic characteristics and/or increase durability of insecticidal proteins in plants
WO2025186719A1 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions and uses thereof
WO2025201243A1 (zh) * 2024-03-25 2025-10-02 中国医学科学院医学生物学研究所 重组呼吸道合胞病毒融合前f蛋白突变体和其用途
CN119569836B (zh) * 2025-02-07 2025-07-15 复星安特金(成都)生物制药有限公司 Rsv f蛋白突变体及其应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
JP3816518B2 (ja) 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド 相補的なアデノウイルスベクター系と細胞系
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
EP1445322B2 (en) 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5891690A (en) 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
US6485958B2 (en) 1996-07-01 2002-11-26 Gencell Sa Method for producing recombinant adenovirus
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
NZ335947A (en) 1996-11-20 2000-12-22 Introgen Therapeutics Inc A method for the production and purification of adenoviral vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
EP0973866A4 (en) 1997-03-04 2000-04-19 Baxter Int ADENOVIRUS E1-COMPLEMENTING CELL LINES
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
ATE371020T1 (de) 1998-02-17 2007-09-15 Schering Corp Virusenthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
ATE421337T1 (de) 1998-11-16 2009-02-15 Introgen Therapeutics Inc Adenovirus-formulierungen zur gentherapie
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
EP1054064B2 (en) 1999-05-17 2009-12-16 Crucell Holland B.V. Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
CA2399321C (en) 2000-03-07 2013-04-30 Robert K. Evans Adenovirus formulations
AUPR878401A0 (en) 2001-11-09 2001-12-06 Biota Holdings Ltd Methods for identifying or screening anti-viral agents
EP1453536A4 (en) 2001-12-12 2009-08-26 Mayne Pharma Int Pty Ltd COMPOSITION FOR PRESERVING VIRUSES
IL162404A0 (en) 2002-01-18 2005-11-20 Schering Ag Stabilized formulations of adenovirus
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
CN100497639C (zh) 2002-04-25 2009-06-10 克鲁塞尔荷兰公司 生产腺病毒载体的手段和方法
DK1506287T3 (da) 2002-05-14 2007-08-20 Merck & Co Inc Fremgangsmåder til oprensning af adenovirus
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
AU2003268210A1 (en) 2002-08-28 2004-03-19 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
AU2005214090B2 (en) 2004-02-23 2008-09-11 Crucell Holland B.V. Virus purification methods
ES2317517T5 (es) 2005-04-11 2016-01-21 Crucell Holland B.V. Purificación de virus usando ultrafiltración
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
WO2007110409A1 (en) 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
US7901388B2 (en) 2007-07-13 2011-03-08 Bacoustics, Llc Method of treating wounds by creating a therapeutic solution with ultrasonic waves
JP5711972B2 (ja) 2007-12-24 2015-05-07 アイディー バイオメディカル コーポレイション オブ ケベック 組換えｒｓｖ抗原
NZ593235A (en) 2008-11-03 2013-02-22 Crucell Holland Bv Method for the production of recombinant adenovirus serotype 35
EP2445527A2 (en) 2009-06-24 2012-05-02 ID Biomedical Corporation of Quebec Vaccine
MX2012000035A (es) 2009-06-24 2012-02-28 Id Biomedical Corp Quebec Antigenos de virus de sincicio respiratorio recombinantes.
DK3178490T3 (da) 2009-07-15 2022-06-20 Glaxosmithkline Biologicals Sa RSV F-proteinsammensætninger og fremgangsmåder til fremstilling af disse
EA023179B1 (ru) 2009-08-13 2016-05-31 Круселл Холланд Б.В. Антитела против респираторного синцитиального вируса (pcb) и способы их применения
MX2012004221A (es) 2009-10-15 2012-06-08 Crucell Holland Bv Proceso para purificacion de adenovirus de cultivos de alta densidad celular.
US8460920B2 (en) 2009-10-15 2013-06-11 Crucell Holland B.V. Method for the purification of adenovirus particles
US20120315270A1 (en) 2009-10-21 2012-12-13 The United States Of America, As Represented By The Rsv immunogens, antibodies and compositions thereof
KR101820980B1 (ko) 2010-02-15 2018-01-22 얀센 백신스 앤드 프리벤션 비.브이. Ａｄ 26 아데노바이러스 벡터를 제조하는 방법
CN106188284B (zh) * 2010-07-09 2020-05-08 扬森疫苗与预防公司 抗人呼吸道合胞病毒(rsv)抗体以及使用方法
AU2012255971A1 (en) * 2011-05-13 2013-05-02 Novartis Ag Pre-fusion RSV F antigens
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
CA2864956C (en) 2012-03-12 2021-11-09 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
EP2827894B1 (en) 2012-03-22 2017-05-17 Janssen Vaccines & Prevention B.V. Vaccine against rsv
JP2013247240A (ja) 2012-05-25 2013-12-09 Gigaphoton Inc レーザ装置
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
RU2021132097A (ru) 2013-03-13 2022-03-03 Дзе Юнайтед Стэйтс Оф Америка, Эс Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз Белки rsv f в предшествующей слиянию конформации и их применение
JP6416212B2 (ja) 2013-04-15 2018-10-31 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖｇタンパク質に結合するヒト抗体
WO2014170257A1 (en) 2013-04-15 2014-10-23 Crucell Holland B.V. Human antibodies binding to rsv g protein
US10899800B2 (en) 2013-04-25 2021-01-26 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
MX362792B (es) 2013-06-17 2019-02-13 Janssen Vaccines & Prevention Bv Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados.

Also Published As

Publication number Publication date
ZA201509140B (en) 2022-03-30
SG11201510216RA (en) 2016-01-28
CN105408348A (zh) 2016-03-16
CA2914792C (en) 2024-02-27
US10294279B2 (en) 2019-05-21
EP3010931B1 (en) 2018-06-13
MY171210A (en) 2019-10-02
JP2016522230A (ja) 2016-07-28
EA201690031A1 (ru) 2016-07-29
AU2014283334B2 (en) 2018-10-18
NZ714594A (en) 2021-07-30
CL2015003655A1 (es) 2016-06-03
US20160176932A1 (en) 2016-06-23
AP2015008893A0 (en) 2015-12-31
CN105408348B (zh) 2021-07-06
AU2014283334A1 (en) 2015-12-17
HK1223949A1 (zh) 2017-08-11
EP3010931A1 (en) 2016-04-27
PH12015502735B1 (en) 2019-06-14
BR112015031509A2 (pt) 2017-08-29
PH12015502735A1 (en) 2016-03-07
BR112015031509B1 (pt) 2023-05-09
IL243053B (en) 2020-06-30
EA034653B1 (ru) 2020-03-03
KR102313153B1 (ko) 2021-10-15
JP6679475B2 (ja) 2020-04-15
KR20160021196A (ko) 2016-02-24
MX362792B (es) 2019-02-13
MX2015017771A (es) 2016-10-04
CA2914792A1 (en) 2014-12-24
WO2014202570A1 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
PE20160045A1 (es) Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados
CY1121600T1 (el) Σταθεροποιημενα διαλυτα πολυπεπτιδια rsv f προσυντηξης
DOP2021000022A (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
CY1124019T1 (el) Σταθεροποιημενη διαλυτη πρωτεϊνη προσυντηξης rsv f για χρηση στην προφυλαξη απο λοιμωξη rsv
EA201890235A1 (ru) Стабилизированные растворимые f-полипептиды rsv до слияния
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
MX2018012166A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
EA202090014A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA201892702A1 (ru) Стабилизированные f-белки rsv до слияния
MX2021000773A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo.
BR112019008781A2 (pt) poxvírus quiméricos sintéticos
MX2018000570A (es) Nuevas isoformas de tripsina y su uso.
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
BR112017004000A2 (pt) formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)óxi)-n,2-dimetilbenzofuran-3-carboxamida
MX389026B (es) Una composicion farmaceutica y el uso de la misma.
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
BR112018011085A2 (pt) composições farmacêuticas contendo doravirina, fumarato de tenofovir desoproxila e lamivudina
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
MX382841B (es) Producto para el cuidado bucal y métodos para uso y fabricación de este.
EA201892157A1 (ru) Фосфаплатиновые жидкие составы
EP4461365A3 (en) Respiratory syncytial virus (rsv) vaccine
EA201991993A1 (ru) Применение фенилкреатина в качестве ноотропного агента
AR095869A1 (es) Anticuerpos humanos que se unen a la proteína g del rsv
TR201910467T4 (tr) Selektif PYY bileşikleri ve bunların kullanımları.
TH153766A (th) อนุพันธ์ พิเพอริดิโน-ไพริมิดีน สำหรับการรักษาการติดเชื้อไวรัส